Antitrust, Market Exclusivity, and Transparency in the Pharmaceutical Industry

Click here to read the full article online

Exclusive dealing and bundling are often viewed as procompetitive. But in 3 recent cases, drug companies have claimed that these practices prevented their products from obtaining market share. This short piece summarizes the 3 cases and the relevant antitrust principles.